Keeping Track: Year-End Submissions Rush Brings Seven Novel Agents To US FDA
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.